Applications for phase three of the Pathway Transformation Fund (PTF) are now open.
The fund supports NHS organisations increase their adoption of the 2020/21 Rapid Uptake Products RUPs, which are:
- Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
- Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
- Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
The PTF can help providers overcome practical obstacles to introducing these products, such as:
- Support set-up costs such as training and accreditation of staff;
- Pathway redesign and/or business support expertise;
- Providing funding for specialist nurses and clinical staff needed to implement a new part of the procedure; and
- Covering double running costs
- Capital costs.
NHS organisations will be able to submit applications for PTF until 12 noon, 30 April 2021. Applications should be developed and submitted with the support of your local AHSN RUP lead – please email info@innovationagencynwc.nhs.uk for further details.
News and blogs >
Mersey Burns: successful innovator/clinician collaboration Read more
Professor Rowan Pritchard Jones, decided he needed to take action to help treat patients with traumatic burns injuries more safely: by automating the calculation of fluid balance requirements for burns victims, which is critical to survival.
Collaborating for medicines safety Read more
A programme to reduce the avoidable harm caused by opioids is now on a firm footing in the North West Coast.
Launch of new lipid management pathway Read more
Clinicians in Cheshire and Merseyside have collaborated on a new lipid management pathway aimed at improving outcomes for people with cardiovascular disease (CVD).
Mental health innovators to benefit from £20m programme Read more
Health Innovation North West Coast is backing a programme to support innovators working at the forefront of mental health therapeutics
